Get Retatrutide Online in Delaware | OmniRx Health

Medical Weight Loss Treatment in Delaware

Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).

Key Benefits

Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
~58% hepatic fat reduction in Phase 2 sub-group analyses
Elevated basal metabolic rate via glucagon receptor agonism
Research-grade purity ≥98% with full CoA, HPLC, and MS documentation

Who is a Good Candidate?

Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.

Available for research use

Serving Delaware

Delaware may be small, but its healthcare needs are mighty. From Wilmington's bustling business district to the beaches of Rehoboth, OmniRx Health delivers personalized telemedicine to the First State. Our compact size works in your favor—whether you're in New Castle County or Sussex County, you're just a video call away from board-certified providers who understand Delaware's unique community health landscape.

Our providers are licensed by the Delaware Board of Medical Licensure and Discipline for statewide telehealth services.

Delaware pharmacies in Wilmington, Dover, Newark, and across all three counties partner with us for seamless prescription services.

Delaware's telehealth regulations support comprehensive virtual care, allowing providers to establish patient relationships through secure video consultations.

Delaware insurers are required to cover telehealth services, and the state's compact size means quick prescription delivery statewide.

Frequently Asked Questions

What is retatrutide and how does it work?: Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
How does retatrutide compare to semaglutide and tirzepatide in research?: Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
Is retatrutide available for human use?: No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
Is telehealth legal in Delaware?: Yes, telehealth is fully legal in Delaware. The state supports virtual healthcare delivery, allowing licensed providers to offer consultations, prescribe medications, and manage ongoing care remotely.
How quickly can I receive prescriptions in Delaware?: Given Delaware's compact geography, most prescriptions arrive within 1-2 business days. We partner with pharmacies throughout the state for fast, reliable delivery to your doorstep.
Can I use telehealth for ongoing treatment in Delaware?: Absolutely. Telehealth is ideal for managing chronic conditions, ongoing medication management, and regular check-ins. Delaware law supports continuing care relationships through virtual platforms.